Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo
Company profile
Ticker
SNY
Exchange
Website
CEO
Olivier Brandicourt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SANOFI SYNTHELABO SA, SANOFI-AVENTIS
SEC CIK
Corporate docs
IRS number
133529324
SNY stock data
Latest filings (excl ownership)
F-3ASR
Automatic shelf registration (foreign)
4 Apr 24
S-8
Registration of securities for employees
4 Apr 24
6-K
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
20 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Mar 24
6-K
Current report (foreign)
27 Feb 24
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
23 Feb 24
6-K
Current report (foreign)
15 Feb 24
6-K
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
2 Feb 24
6-K
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
1 Feb 24
6-K
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
23 Jan 24
Latest ownership filings
SC 13G/A
Amundi
14 Feb 24
SC 13G/A
DODGE & COX
13 Feb 24
SC 13G/A
BlackRock Inc.
6 Feb 24
SC 13G
MeiraGTx Holdings plc
6 Nov 23
11-K
Annual report of employee stock purchases
28 Jun 23
11-K
Annual report of employee stock purchases
28 Jun 23
SC 13G/A
DODGE & COX
14 Feb 23
SC 13G/A
Amundi
10 Feb 23
SC 13G/A
BlackRock Inc.
7 Feb 23
11-K
Annual report of employee stock purchases
29 Jun 22
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
9.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 667 |
Opened positions | 69 |
Closed positions | 45 |
Increased positions | 262 |
Reduced positions | 200 |
13F shares | Current |
---|---|
Total value | 13.42 tn |
Total shares | 250.33 mm |
Total puts | 1.24 mm |
Total calls | 1.45 mm |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
Dodge & Cox | 78.51 mm | $4.21 tn |
FMR | 22.80 mm | $1.22 tn |
Fisher Asset Management | 14.94 mm | $801.53 bn |
Boston Partners | 12.79 mm | $680.70 bn |
BAC Bank Of America | 10.58 mm | $567.73 bn |
BLK Blackrock | 9.81 mm | $526.02 bn |
MS Morgan Stanley | 7.32 mm | $392.80 bn |
IVZ Invesco | 6.83 mm | $366.42 bn |
BK Bank Of New York Mellon | 5.65 mm | $303.10 bn |
Nuveen Asset Management | 4.20 mm | $225.19 bn |
News
Sanofi's Rilzabrutinib LUNA 3 Phase 3 Study Met Primary Endpoint In Immune Thrombocytopenia
23 Apr 24
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
21 Apr 24
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
17 Apr 24
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years
17 Apr 24
Sanofi's Multiple Sclerosis Antibody Shows Reduction Of Disease Activity
17 Apr 24
Press releases
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
10 Feb 24
CytoReason's AI-Driven Disease Model Platform Trusted By 5 Top 10 Pharma Companies Harnesses Big Data To Speed Drug Discovery And Development
6 Feb 24